Research programme: chimeric antigen receptor-targeted therapies - Novartis/University of Pennsylvania

Drug Profile

Research programme: chimeric antigen receptor-targeted therapies - Novartis/University of Pennsylvania

Alternative Names: Adoptive T-cell immunotherapies - University of Pennsylvania/Novartis; CAR immunotherapies - University of Pennsylvania/Novartis

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Novartis; University of Pennsylvania
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
  • 10 Oct 2014 Oxford BioMedica and Novartis enter into a process development and manufacturing collaboration for the LentiVector® technology, and tisagenlecleucel-T and other CAR T cell therapies
  • 31 Jul 2013 Life Technologies and Novartis enter a long-term supply and license agreement for Dynabead®CD3/CD28 CTS™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top